Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genesLucas Hoffmann, Samir Jabari, Jochen Herms et al.|Acta Neuropathologica|2023Cited by 24
Molecular signatures define <i>BAP1</i>-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genesPhilipp Sievers, Felix Sahm, Sonali Arora et al.|Neuro-Oncology|2025Cited by 14
Correction to: Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genesLucas Hoffmann, Samir Jabari, Roland Coras et al.|Acta Neuropathologica|2023Cited by 3
Alterations in <i>PTPN11</i> and other RAS-/MAP-Kinase pathway genes define ganglioglioma with adverse clinical outcome and atypic histopathological featuresLucas Hoffmann, Samir Jabari, Roland Coras et al.|medRxiv|2022Cited by 0